---
figid: PMC9357610__JCMM-26-4548-g001
pmcid: PMC9357610
image_filename: JCMM-26-4548-g001.jpg
figure_link: /pmc/articles/PMC9357610/figure/jcmm17478-fig-0002/
number: FIGURE 2
figure_title: ''
caption: 'Pirfenidone alleviated cardiac fibrosis induced by TAC in mice. (A–C) Picrosirius
  red (PSR) staining and quantitative results of cardiac perivascular. (B) and interstitial.
  (C) fibrosis (n = 6 per experiment group). Scale bar = 50 μm. (D, E) Immunohistochemistry
  (IHC) images and relative expression of α‐SMA in mouse heart sections (n = 6 each
  group). Scale bar = 50 μm. (F, G) Western blotting and relative expression of α‐SMA
  in mouse heart tissue(n = 5–6). (H, I) IHC images and relative expression of Vimentin
  in mice heart sections (n = 6 each group). Scale bar = 50 μm. (J, K) Western blotting
  and relative expression of Vimentin in mouse heart tissue (n = 6). *p < 0.05, **
  p < 0.01 vs. Sham group; #p < 0.05, ##p < 0.01 vs. TAC group'
article_title: Pirfenidone alleviates cardiac fibrosis induced by pressure overload
  via inhibiting TGF‐β1/Smad3 signalling pathway.
citation: Na Li, et al. J Cell Mol Med. 2022 Aug;26(16):4548-4555.
year: '2022'

doi: 10.1111/jcmm.17478
journal_title: Journal of Cellular and Molecular Medicine
journal_nlm_ta: J Cell Mol Med
publisher_name: John Wiley and Sons Inc.

keywords:
- cardiac fibrosis
- cardiac remodelling
- pirfenidone
- pressure overload
- transforming growth factor‐β1

---
